Welcome to our dedicated page for IREN SEC filings (Ticker: IREN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the intersection of Bitcoin volatility and renewable power costs inside ±õ¸é·¡±·â€™s SEC disclosures can feel like decoding two industries at once. Hash-rate calculations, energy purchase agreements, and digital-asset impairments sprawl across hundreds of pages, while insider sales arrive without warning.
That’s why Stock Titan pairs AI-powered summaries with real-time EDGAR feeds. Whether you need the IREN quarterly earnings report 10-Q filing or an IREN 8-K material events explained notification, our platform delivers every document seconds after it posts and breaks it down in plain language. Use our AI to surface renewable energy contract terms, spot non-cash impairment charges, or compare hash-rate disclosures quarter over quarter—no accounting degree required.
Looking for governance insights? Instantly scan IREN proxy statement executive compensation tables or monitor IREN insider trading Form 4 transactions with automatic alerts. Need trading context? The dashboard links IREN Form 4 insider transactions real-time to price charts, helping you correlate executive moves with market shifts.
- Annual clarity: Read the IREN annual report 10-K simplified to see mining economics, cap-ex outlays, and renewable power hedges.
- Quarterly pulse: Get concise IREN earnings report filing analysis moments after the call ends.
- Event radar: Automatic alerts flag every new 8-K, so you never miss a turbine outage or new hosting contract.
From “understanding IREN SEC documents with AI� to tracking IREN executive stock transactions Form 4, Stock Titan gives professionals the context they need—faster, clearer, and always up-to-date.
IREN Limited filed a Form 8-K on 1 July 2025 reporting a single corporate event: the appointment of Anthony Lewis as Chief Capital Officer. The new C-suite role is expected to oversee the company’s capital structure and funding strategy. The disclosure is limited to the leadership change; no financial results, guidance, transactions, or other material developments are included. The announcement is provided in Exhibit 99.1 (press release) and the filing is signed by Co-CEO Daniel Roberts. Consequently, the document has low financial complexity and is primarily informative for corporate governance tracking.
Kineta, Inc. (symbol: KA), now operating as Kineta, LLC following its June 30, 2025 closing of the merger with TuHURA Biosciences, filed Post-Effective Amendment No. 1 to nine previously effective Form S-8 registration statements.
The filing deregisters all remaining, unsold shares—covering roughly 13 million shares in the aggregate—originally registered for issuance under multiple legacy equity compensation plans of Kineta, Proteostasis Therapeutics, and Yumanity Therapeutics. Because the company ceased to exist as a standalone issuer at the effective time of the two-step merger, these equity offerings are terminated and the corresponding securities are removed from registration.
There are no new securities issuances, capital raises, or financial figures in this amendment; it is an administrative action to satisfy Securities Act undertakings. The submission also confirms Kineta’s status as a non-accelerated filer and smaller reporting company, and it is signed by President James A. Bianco, M.D.
For investors, the amendment signals completion of post-merger housekeeping. All future equity grants will occur under TuHURA’s registration statements, while legacy plans are effectively retired.